699 BOYLSTON ST STE 8 BOSTON, MA 02116 Get Directions
699 BOYLSTON ST STE 8 BOSTON, MA 02116 Get Directions
Zalicus is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. Zalicus has a portfolio of proprietary clinical-stage product candidates targeting pain, including Z160, an N-type calcium channel blocker for chronic neuropathic pain and Z944, a T-type calcium channel blocker for acute and inflammatory pain. We have entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. Zalicus applies its expertise in the discovery and development of selective ion channel modulators and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease.
© Dun & Bradstreet, Inc. 2024. All rights reserved.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.